Related Experiment Video
Updated: Feb 15, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
13.4K
Cellular therapies for chronic ischemic heart failure.
Rosalie M Sterner1, Robert C Sterner2, Jorge A Brenes-Salazar3
1Mayo Clinic Medical Scientist Training Program, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Summary
Stem cell therapy for chronic ischemic heart failure shows mixed results, with some studies indicating modest efficacy. Further research is needed to optimize cell types and delivery for improved patient outcomes.
Area of Science:
- Regenerative Medicine
- Cardiology
- Clinical Trials
Background:
- Chronic ischemic heart failure significantly impacts morbidity and mortality.
- Stem cell therapy is a promising avenue for treating heart failure.
- Clinical trials are essential to evaluate the efficacy and safety of these therapies.
Purpose of the Study:
- To review existing clinical trials on stem cell therapy for chronic ischemic heart failure.
- To summarize the findings and identify challenges in current stem cell treatments for heart failure.
- To highlight areas for future research and optimization of stem cell therapies.
Main Methods:
- A systematic literature search was conducted on PubMed using "stem cell therapy heart failure" and "Clinical Trial" filters.
- The initial search yielded 156 articles; 53 were selected for review.
- Additional relevant articles were identified through manual research and cross-referencing.
Main Results:
- Cellular therapies, including peripheral blood progenitor cells, bone marrow cells, mesenchymal stem cells, cardiac cells, and embryonic stem cells, have shown varied outcomes.
- Some studies reported modest efficacy, while others yielded mixed results.
- Skeletal myoblasts raised safety concerns due to potential arrhythmias.
Conclusions:
- Optimizing cell type and delivery methods is crucial for enhancing stem cell therapy efficacy in heart failure patients.
- Continued research and development are necessary to overcome current limitations.
- Stem cell therapies hold significant potential to reduce the health burden of chronic ischemic heart failure.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
402
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
402
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
01:17Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
01:27Heart Failure I: Introduction
966
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
966
01:22Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
01:30Heart Failure V: Medical Management
369
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
369